Technical Analysis for RUBY - Rubius Therapeutics, Inc.
|Grade||Last Price||% Change||Price Change|
RUBY closed down 13.88 percent on Thursday, December 13, 2018, on 1.6 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
|Weak or Absent||N/A||Down||Down|
|See historical RUBY trend table...|
|Date||Alert Name||Type||% Chg|
|Dec 13||Fell Below 50 DMA||Bearish||0.00%|
|Dec 13||Expansion Pivot Sell Setup||Bearish Swing Setup||0.00%|
|Dec 13||Multiple of Ten Bearish||Other||0.00%|
|Dec 13||Strong but Oversold||Other||0.00%|
|Dec 13||Below Lower BB||Weakness||0.00%|
|Dec 13||Lower Bollinger Band Touch||Weakness||0.00%|
|Dec 13||Oversold Stochastic||Weakness||0.00%|
|Dec 12||20 DMA Resistance||Bearish||-13.88%|
|Dec 12||Multiple of Ten Bearish||Other||-13.88%|
|Dec 12||Strong but Oversold||Other||-13.88%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
- Earnings date: 2018-11-30
Rubius Therapeutics Inc is a biotechnology company that develops cellular therapies for cancer, and enzyme deficiency diseases. The Company develops Red-Cell Therapeutics (RCT) products using red platform. RCT is a red blood cell-based therapy for applications in cancer, enzyme replacement therapies, and autoimmune disease and tolerance induction. Its RCT product candidate is designed to provide various attributes, which include broad therapeutic applications, predictable bio-distribution and advantageous tolerability. It is initially focused on advancing RCT product candidates for patients suffering from rare diseases, cancer and autoimmune diseases based on three modalities - cellular shielding, potent cell-cell interaction and tolerance induction. Its product candidates in rare diseases include RTX-134 for the treatment of phenylketonuria (PKU), RTX-134 followed by RTX-Uricase and RTX-CBS for the treatment of chronic refractory gout symptomatic homocystinuria.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more RUBY news...
|52 Week High||33.01|
|52 Week Low||14.5|
|200-Day Moving Average||0.0|
|50-Day Moving Average||18.5246|
|20-Day Moving Average||20.3325|
|10-Day Moving Average||20.367|
|Average True Range||1.8001|
|Chandelier Exit (Long, 3 ATRs )||18.5797|
|Chandelier Exit (Short, 3 ATRs )||19.9003|
|Upper Bollinger Band||23.2869|
|Lower Bollinger Band||17.3781|
|Percent B (%b)||-0.05|
|MACD Signal Line||0.5337|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||21.86|
|Resistance 3 (R3)||22.37||21.29||21.06|
|Resistance 2 (R2)||21.29||20.06||21.03||20.79|
|Resistance 1 (R1)||19.17||19.31||18.63||18.66||20.53|
|Support 1 (S1)||15.97||16.86||15.43||15.46||13.59|
|Support 2 (S2)||14.89||16.11||14.63||13.33|
|Support 3 (S3)||12.77||14.89||13.06|
|Support 4 (S4)||12.26|